ST. LOUIS, June 22 /PRNewswire/ -- Auxeris Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of medicines to treat a broad range of bone diseases, today announced that William J. Boyle, Ph.D., joined the company as Chief Scientific Officer to lead development of several drug candidates for the prevention of osteoporosis and the treatment of bone metastases.
"Bill brings 15 years of industry experience in bone biology, drug discovery and biologics development to Auxeris. His depth and breadth of experience in the development of biopharmaceuticals is a significant asset to Auxeris that will help the company become a leader in the development of innovative therapies for bone diseases," said Laurent Fischer, M.D., President and CEO of Auxeris.
Prior to joining Auxeris, Dr. Boyle led experimental research platforms at Protein Pathways as Vice President of Biology. He was formerly Director of Discovery Research and the Biosystems Technology Platforms at Amgen where he led the preclinical and clinical development of osteoprotegerin (OPG), a natural endogenous factor protecting bone from resorption. Dr. Boyle received his Bachelors and Masters degrees in Biology from UCLA, and a Doctoral degree in Experimental Pathology from the UCLA School of Medicine. He pursued postdoctoral studies at the Salk Institute as a Howard Hughes Fellow. Dr. Boyle has published extensively and received numerous awards for his research in the area of bone physiology and RANKL, the primary cytokine responsible for bone resorption. He recently co-authored a review paper entitled "Osteoclast differentiation and activation," which was published in the journal Nature in May 2003 (vol. 423). Dr. Boyle's research interests include elucidating the molecular and cellular biology of key signaling and metabolic pathways linked to disease.
Auxeris Therapeutics, Inc. ("Auxeris") is a biopharmaceutical company focused on the development and commercialization of proprietary breakthrough medicines to treat a broad range of bone diseases. The Company's first two products, a novel injectable anti-resorptive to treat bone metastases and the first oral bone anabolic drug for the prevention of osteoporosis, represent novel treatment approaches and are expected to enter clinical trials in the next eighteen months. Auxeris was founded in 2002 based on the technology of Drs. Steven Teitelbaum and Patrick Ross of Washington University School of Medicine. In January 2004, Auxeris acquired the technology assets from Ceros Pharmaceuticals, a company founded by Dr. Gerard Karsenty of Baylor. The company has raised a $4.1 million series A from Domain Associates of Princeton, NJ and RiverVest Ventures Partners of St. Louis, MO. For more information, visit the company website at http://www.auxeris.com/.
For further information, please contact: Virginia Amann of Atkins + Associates, +1-608-274-6046, email@example.com, for Auxeris Therapeutics Inc.; or Laurent Fischer, MD, President & CEO of Auxeris Therapeutics Inc., +1-314-633-1881, firstname.lastname@example.org.
Auxeris Therapeutics Inc.
CONTACT: Virginia Amann of Atkins + Associates,+1-608-274-6046, email@example.com, for Auxeris Therapeutics Inc.; or LaurentFischer, MD, President & CEO, +1-314-633-1881, firstname.lastname@example.org